Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer 2020; 9(02): 090-092
DOI: 10.1055/s-0040-1721211
Original Article: Gynaecological Cancer

A Tertiary Cancer Center Experience of 52 Cases of Primary Ovarian Mucinous Adenocarcinomas

Gaurav Das
1   Department of Surgical Oncology, Cancer Institute (WIA), Chennai, Tamil Nadu, India
,
V. Sridevi
1   Department of Surgical Oncology, Cancer Institute (WIA), Chennai, Tamil Nadu, India
2   Division of Gynecologic Oncology, Department of Surgical Oncology, Cancer Institute (WIA), Chennai, Tamil Nadu, India
,
Mohanaraj Natarajan
1   Department of Surgical Oncology, Cancer Institute (WIA), Chennai, Tamil Nadu, India
› Author Affiliations Funding None.
› Further Information
   Permissions and Reprints

Abstract

Background Primary mucinous epithelial ovarian adenocarcinoma (mEOC) constitutes a small percentage (2–5%) of ovarian cancer. Our aim is to understand the clinicopathological characteristics and survival results of patients with mEOC after a long-term follow-up.

Materials and Methods This is a retrospective study of primary mEOC cases treated at a tertiary cancer center in India, from January 1, 2005, to December 31, 2012.

Results Out of 958 malignant ovarian tumors, 52 (5.43%) were mucinous adenocarcinoma. Nearly 71.2% of cases were of early-stage disease, and the remaining were of advanced-stage disease. After a follow-up period of 63 months (range: 1–138 months), the 5-year actuarial overall survival for stages I, II, III, and IV was 92.5, 70, 38.5, and 0%, respectively. Among advanced-stage tumors, half of them progressed without undergoing cytoreductive surgery and died.

Conclusion Most of the mEOC cases present in early stages and have good clinical outcome. Patients with advanced-stage disease do not respond well to standard chemotherapy regimens in use and have poor survival figures. The use of primary cytoreduction should be considered in the place of interval cytoreduction for advanced mEOC.

Keywords

cytoreductive surgery - mucinous adenocarcinoma - neoadjuvant chemotherapy - ovarian cancer


Publication History

Article published online:
14 December 2020

© 2020. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 Seidman JD, Kurman RJ, Ronnett BM. Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis. Am J Surg Pathol 2003; 27: 985-993
    CrossrefPubMedGoogle Scholar
  • 2 Shimada M, Kigawa J, Ohishi Y. et al. Clinicopathological characteristics of mucinous adenocarcinoma of the ovary. Gynecol Oncol 2009; 113: 331-334
    CrossrefPubMedGoogle Scholar
  • 3 Bookman MA, Brady MF, McGuire WP. et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol 2009; 27: 1419-1425
    CrossrefPubMedGoogle Scholar
  • 4 Swaminathan R. Population Based Cancer Registry, Chennai. Available at: https://ncdirindia.org/Reports.aspx
  • 5 Seidman JD, Horkayne-Szakaly I, Haiba M. et al. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol 2004; 23: 41-44
    CrossrefPubMedGoogle Scholar
  • 6 Hess V, A’Hern R, Nasiri N. et al. Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol 2004; 22: 1040-1044
    CrossrefPubMedGoogle Scholar
  • 7 Hart WR. Diagnostic challenge of secondary (metastatic) ovarian tumors simulating primary endometrioid and mucinous neoplasms. Pathol Int 2005; 55: 231-243
    CrossrefPubMedGoogle Scholar
  • 8 Ji H, Isacson C, Seidman JD, Kurman RJ, Ronnett BM. Cytokeratins 7 and 20, dpc4, and MUC5AC in the distinction of metastatic mucinous carcinomas in the ovary from primary ovarian mucinous tumors: Dpc4 assists in identifying metastatic pancreatic carcinomas. Int J Gynecol Pathol 2002; 21: 391-400
    CrossrefPubMedGoogle Scholar
  • 9 McCluggage WG, Young RH. Immunohistochemistry as a diagnostic aid in the evaluation of ovarian tumors. Semin Diagn Pathol 2005; 22: 3-32
    CrossrefPubMedGoogle Scholar
  • 10 Lee KR, Young RH. The distinction between primary and metastatic mucinous carcinomas of the ovary: Gross and histologic findings in 50 cases. Am J Surg Pathol 2003; 27: 281-292
    CrossrefPubMedGoogle Scholar
  • 11 Zaino RJ, Brady MF, Lele SM. et al. Advanced stage mucinous adenocarcinoma of the ovary is both rare and highly lethal: a gynecologic oncology group study. Cancer 2011; 117: 554-562
    CrossrefPubMedGoogle Scholar